Quetzal Therapeutics is pioneering a new paradigm in the treatment of rare hematologic malignancies and rare diseases.
Our lead candidate, QTX-2101, targets APL with a novel approach to improve outcomes.
We are preparing for Phase III clinical trials in late 2025, with registration-enabling activities currently underway.
Leveraging proprietary delivery systems and optimized formulations, we’re expanding our portfolio with additional programs in development—advancing a pipeline built to address unmet clinical needs.
In addition to QTX-2101, we are actively pursuing clinical programs with the potential to reshape treatment paradigms across oncology and rare disease spaces.